Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 1, 2009, Pages 172-178

  Martinez Gomez J M ^a   Johansen, P ^a   Rose, H ^b   Steiner, M ^b   Senti, G ^a   Rhyner, C ^c   Crameri, R ^c   Kundig T M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Digilab BioVisioN GmbH   (Germany)

^c SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

Allergy; Immunotherapy; Invariant chain; Recombinant proteins; TAT protein

Indexed keywords

ANTIALLERGIC AGENT; FEL D 1 ALLERGEN; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; LEUKOTRIENE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAT FEL D 1 ALLERGEN; RECOMBINANT ALLERGEN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALLERGY TEST; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BASOPHIL; BASOPHIL DEGRANULATION TEST; CAT DANDER ALLERGY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN VARIANT; TH1 CELL; VACCINATION;

ALLERGENS; ANIMALS; ANTIBODY FORMATION; ANTIGEN PRESENTATION; BASOPHILS; CATS; CELL DEGRANULATION; DRUG DELIVERY SYSTEMS; DRUG TOXICITY; GLYCOPROTEINS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; MICE; RECOMBINANT PROTEINS; TH1 CELLS;

EID: 58149136998     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2008.01812.x     Document Type: Article

References (31)

1. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy 2001 56 : 301 306.
2. Karamloo F, Schmid-Grendelmeier P, Kussebi F, Akdis M, Salagianni M, von Beust BR et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005 35 : 3268 3276.
3. Saarne T, Kaiser L, Gronlund H, Rasool O, Gafvelin G, van Hage-Hamsten M. Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin Exp Allergy 2005 35 : 657 663.
4. Larche M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007 119 : 906 909.
5. Johansen P, Senti G, Martinez Gomez JM, Storni T, von Beust BR, Wuthrich B et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005 35 : 1591 1598.
6. Santeliz JV, Nest GV, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002 109 : 455 462.
7. Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007 120 : 278 285.
8. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007 120 : 707 713.
9. Barbey C, Donatelli-Dufour N, Batard P, Corradin G, Spertini F. Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323-339 generates interleukin-10 secreting T cells and results in the induction of allergen systemic tolerance. Clin Exp Allergy 2004 34 : 654 662.
10. Kundig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006 117 : 1470 1476.
11. Martinez Gomez JM, Fischer S, Csaba N, Kundig TM, Merkle HP, Gander B et al. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res 2007 24 : 1927 1935.
12. Kopp MV, Stenglein S, Kamin W, Friedrichs F, von Berg A, Zielen S et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol 2007 18 : 523 527.
13. Johansen P, Senti G, Martinez Gomez JM, Wuthrich B, Bot A, Kundig TM. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol 2005 35 : 3591 3598.
14. García-Sellés J, Pascual A, Funes E, Pagán JA, López JD, Negro JM et al. Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica. Allergol Immunopathol (Madr) 2003 31 : 63 69.
15. Wurtzen PA, Lund L, Lund G, Holm J, Millner A, Henmar H. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity. Int Arch Allergy Immunol 2007 144 : 287 295.
16. Crameri R, Fluckiger S, Daigle I, Kundig T, Rhyner C. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007 62 : 197 206.
17. Fittipaldi A, Giacca M. Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 2005 57 : 597 608.
18. Gump JM, Dowdy SF. TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 2007 13 : 443 448.
19. Herce HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci USA 2007 104 : 20805 20810.
20. Roche PA, Marks MS, Cresswell PJ. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 1991 354 : 392 394.
21. Hiltbold EM, Roche PA. Trafficking of MHC class II molecules in the late secretory pathway. Curr Opin Immunol 2002 14 : 30 35.
22. Johansen P, Haffner AC, Koch F, Zepter K, Erdmann I, Maloy K et al. Direct intralymphatic injection of peptide vaccines enhances immunogenicity. Eur J Immunol 2005 35 : 568 574.
23. Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002 2 : 773 786.
24. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004 113 : 1025 1034 quiz 1035.
25. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Delivery Rev 2005 57 : 559.
26. Bischof F, Wienhold W, Wirblich C, Malcherek G, Zevering O, Kruisbeek AM et al. Specific treatment of autoimmunity with recombinant invariant chains in which CLIP is replaced by self-epitopes. Proceedings of the National Academy of Sciences 2001 98 : 12168 12173.
27. Carstens C, Newman DK, Bohlen H, Konig A, Koch N. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation. Int Immunol 2000 12 : 1561 1568.
28. Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Exp Opin Biol Ther 2006 6 : 1311 1321.
29. Bonehill A, Heirman C, Thielemans K. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. J Gene Med 2005 7 : 686 695.
30. Ruedl C, Bachmann MF, Kopf M. The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur J Immunol 2000 30 : 2056 2064.
31. Powell RJ, Frew AJ, Corrigan CJ, Durham SR. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis. Allergy 2007 62 : 1335 1338.